2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Blood Banking, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Women’s Health, Adverse Events, Biological Processes, Apoptosis, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

2903 A novel treatment for acute pain events, IHP-102, reduces hypoxia-induced inflammatory biomarkers in sickle mouse model

Srija Ponna, MS, Sammi Kim, PhD2, Kennedy Nichelle Goldsborough, PhD3, Rachel Choi, BS4, Eli O'Kane Martin, MS5, Megan Elisa Merritt-Garza, MS6, Ashwin Prahladbhai Patel, MBBS, PhD7, John Paderi, PhD8, Vivien A Sheehan, MD,PhD9
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Emory University School of Medicine, Atlanta, Georgia, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
5 Emory University School of Medicine, Atlanta, Georgia, United States
6 Emory University School of Medicine, Atlanta, Georgia, United States
7 Emory University School of Medicine, Atlanta, Georgia, United States
8 IHP Therapeutics, San Carlos, California, United States
9 Emory University School of Medicine, Atlanta, Georgia, United States

Background: Sickle cell disease (SCD) is an inherited blood disorder caused by an abnormal hemoglobin, HbS, which polymerizes under hypoxia, resulting in adhesive and rigid RBCs that hemolyze and occlude blood vessels, promoting painful vaso-occlusive events (VOEs). Subsequent tissue damage and hemolysis-generated reactive free hemoglobin trigger inflammatory cytokines and complement activation, prolonging and exacerbating VOEs. Tinzaparin was tested as a treatment for acute pain events in SCD as it has anti-adhesive and anti-complement activity, but its anticoagulant effects created an unfavorable safety profile. IHP-102, a novel glycan modified to remove anticoagulant activity, has demonstrated preclinical potential as a safer disease-modifying drug to treat acute VOEs. However, its mechanism of action and biomarkers to follow in planned clinical trials have not been fully elucidated. We evaluated changes in circulating complement and cytokine levels following prophylactic IHP-102 treatment in hypoxia-exposed Townes humanized hemoglobin mice. 

Methods: Townes SCD (HbSS, n=35) and control (HbAA, n=27) mice (10-24 weeks old) were given three treatments via subcutaneous injection: saline (vehicle, n=24), IHP-102 (3 mg/kg or 6 mg/kg, n=23), and tinzaparin (3 mg/kg, n=15). Afterwards, half of the mice were exposed to hypoxia-reperfusion (3 hours at 8% O2, then 1 hour at 21% O2) to induce acute pain, and the rest were maintained at 21% O2 for 4 hours. Peripheral blood was collected 4 hours after hypoxia, and C3a ELISA and inflammatory cytokine panels were conducted on plasma. Data, reported as medians, was analyzed using Mann-Whitney and Dunn’s tests on GraphPad Prism 11.0. 

Results: After hypoxia exposure, HbSS mice, compared to HbAA, had significantly higher levels of C3a (8.164 vs 4.516 ng/mL, p=0.002), IL-2 (1.97 vs 0.939 pg/mL, p=0.004), IL-6 (90.51 vs 14.22 pg/mL, p=0.04), and IL-10 (21.54 vs 11.32 pg/mL, p=0.002). IHP-102 did not have significant effects on cytokines or C3a in either HbAA or HbSS mice at baseline pre-hypoxia. HbSS mice treated with IHP-102 showed significant reduction of hypoxia-induced IL-2 in a dose-dependent manner compared to saline (0.922 pg/mL (IHP-102 3 mg/kg) vs 1.97 pg/mL (saline), p=0.006; 0.806 pg/mL (IHP-102 6 mg/kg) vs 1.97 pg/mL (saline), p< 0.001). Tinzaparin did not significantly reduce IL-2 (1.29 vs 1.97 pg/mL, p=0.12). The 6 mg/kg dose of IHP-102 reduced IL-10 (13.60 vs 21.54 pg/mL, p=0.03), as did tinzaparin (14.38 vs 21.54 pg/mL, p=0.04). These findings correlate with our previous prophylactic pain behavior data, which showed a significant decrease in mechanical allodynia, measured as paw withdrawal frequency (PWF), in HbSS mice treated with IHP-102 at 3 mg/kg (n=22) compared to saline (n=23) at 4 hours post-hypoxia (2.5 vs 3.0 PWF, p=0.025), as well as in mechanical hyperalgesia (4.25 vs 6.00 PWF, p=0.004). C3a and other cytokines tested did not significantly decrease with IHP-102 at the 3 and 6 mg/kg dose or with tinzaparin. 

Discussion: IL-2 and IL-10 increase during acute pain events in individuals with SCD. In HbSS mice, our results show a rise in IL-2 and IL-10 with hypoxia and reperfusion. Pre-hypoxia administered IHP-102 reduced IL-2 and IL-10, along with pain behaviors, in a sickle mouse model, identifying these anti-inflammatory cytokines as promising biomarkers to evaluate IHP-102 in future clinical trials and to elucidate its mechanistic effects. The safety of IHP-102 is supported by unchanging cytokine and C3a levels in both HbAA and HbSS mice after treatment, as well as by the significantly reduced anticoagulant activity relative to tinzaparin in dog model studies. The beneficial effects of IHP-102 on inflammatory biomarkers and pain behavior support its clinical translation for the termination or reduction of acute pain events in SCD patients. Future studies will include a time-course study of cytokines and complements to gain a better understanding of their levels over time after hypoxia exposure and more clearly capture when IHP-102 should be administered for maximal clinical benefit.

Srija Ponna, MS: No relevant conflicts of interest to declare.